Identification of multi-omic pleiotropy factors for peripheral artery disease

Jiaqi Hu, B.A.[1], Cassius I. Ochoa Chaar, M.D., M.P.H., M.S.[2], Hongyu Zhao, Ph.D.[3, 4], Andrew T. DeWan, Ph.D.[1, #]

[1]Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 06510, USA.

[2]Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale School of Medicine, New Haven, CT 06510, USA.

[3]Department of Biostatistics, Yale School of Public Health, New Haven, CT 06510, USA.

[4]Program of Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.

To whom correspondence should be addressed:

Dr. Andrew T. DeWan

Yale School of Public Health

Center for Perinatal, Pediatric and Environmental Epidemiology

1 Church Street, 6th Floor

New Haven, Connecticut, 06510, USA

Email: andrew.dewan@yale.edu

Abstract

Background: Peripheral artery disease (PAD) is prevalent and frequently co-occurs with type 2 diabetes (T2D) and coronary artery disease (CAD). Although shared genetic factors may contribute to these comorbidities, few studies have examined pleiotropy at the transcriptomic and proteomic levels.

Methods: We generated summary statistics for transcriptome-wide (TWAS) and proteome-wide (PWAS) association analyses across PAD, T2D, and CAD. Joint tests for pleiotropy at the variant, transcript, and protein levels were performed using PLACO, and the contributions of these pleiotropic factors to genetic correlations were quantified. Furthermore, we developed pleiotropy models integrating variants, transcripts, and proteins.

Results: In the PAD-T2D analysis, we identified 5 SNPs, 2 predicted transcripts, and 2 predicted proteins that together contributed 2.8% to the genome-wide genetic covariance. In the PAD-CAD analysis, 33 SNPs, 2 predicted transcripts, and 2 predicted proteins accounted for 9.15% of the genetic covariance. Overall, eight pleiotropy models were established, providing a multi-layered framework for categorizing our findings.

Conclusion: Employing a multi-omic framework, this study elucidates the shared genetic architecture of PAD with T2D and CAD. Our findings enhance the understanding of genetic risk factors underlying PAD and its comorbidities, with potential implications for future therapeutic strategies.

Lay summary

This study investigates why peripheral artery disease (PAD) often occurs together with type 2 diabetes (T2D) or coronary artery disease (CAD) by identifying shared genetic risk factors.

- We discovered new PAD-related genetic variants, including rs2138161, which may function through pathways shared between blood vessel function and metabolic processes.

- PAD-T2D comorbidity appears to be closely related to inflammatory pathways, while PAD-CAD comorbidity is more strongly linked to lipid-related pathways, offering insights into disease mechanisms and potential therapeutic targets.

Keywords: peripheral artery disease (PAD); Type 2 Diabetes (T2D); Coronary Artery Disease (CAD); pleiotropy; multi-omic.

Introduction

Peripheral artery disease (PAD) is a prevalent and severe disease, with the number of people living with PAD rising from 202 million in 2010[1] to 236 million in 2015[2]. Type 2 diabetes (T2D) is a well-established risk factor for PAD[1,3], with recent meta-analyses indicating a 1.96-fold increased risk of PAD in women and a 1.84-fold increase in men with diabetes[3]. Notably, up to 30% of PAD patients have diabetes[4]. In addition, PAD frequently co-occurs with coronary artery disease (CAD), with 39% of PAD patients diagnosed with CAD[5]. CAD is also a leading cause of death among PAD patients[5]. Understanding the comorbid relationship between T2D, PAD, and CAD may provide critical insights into the underlying etiology of PAD.

Pleiotropy, a phenomenon in which a single nucleotide polymorphism (SNP) or gene influences multiple diseases, may explain the observed comorbidities. The same individual SNPs and genes are related to both PAD and T2D[6–9], as well as both PAD and CAD[8,10,11]. Polygenic scores (PGSs), which aggregate the effects of single genetic markers into an overall risk score, have been constructed for T2D and shown to be significantly associated with the PAD risk[6,9]. Similar findings have been reported for CAD PGSs[12]. The evidence supports a shared genetic risk for PAD-T2D and PAD-CAD comorbidities.

Pleiotropy falls into two main categories: vertical (also known as mediated) and horizontal (also known as biological). Vertical pleiotropy describes the scenario where the observed association between genetic factor and trait A is completely mediated by

its association with trait B. Whereas horizontal pleiotropy describes the scenario where a genetic factor is independently associated with trait A and trait B, or rather, the genetic association with trait B is still observed even after adjusting for trait A. Horizontal pleiotropy can be further categorized into correlated and uncorrelated types, defined by whether a SNP or gene functions via the same molecular pathway in two diseases[9]. Correlated pleiotropy involves SNPs functioning within a multi-omic network encompassing the genome, transcriptome, and proteome for both diseases. Uncorrelated pleiotropy consists of SNPs influencing independent pathways, for example, different transcripts and subsequent proteins. A comprehensive understanding of the molecular mechanisms underlying SNP-disease associations is crucial for revealing the complex etiology of PAD and its comorbidities. Identifying multi-omic pleiotropy factors across multi-omic levels can provide insights into convergent biological pathways that drive disease pathogenesis.

Various studies have been conducted to explore the associations or causal relationships across single- and multi-omic layers contributing to the risk of PAD, T2D, and CAD individually[13–18]. Despite these efforts, few studies have explored the pleiotropy between PAD-T2D and PAD-CAD at the transcriptomic and proteomic levels, making it challenging to categorize pleiotropic SNPs and genes into correlated or uncorrelated types or to model more complex relationships.

This study aims to address these gaps by exploring multi-omic risk profiles of PAD, T2D, and CAD through genome-, transcriptome- and proteome-wide association studies

(TWAS and PWAS). We first establish disease-specific risk profiles and then identify

and analyze pleiotropic genomic, transcriptomic, and proteomic factors. Our results not

only enhance the understanding of PAD pathogenesis, but also elucidate the molecular

mechanisms underlying its comorbidities—facilitating the identification of risk factors

and therapeutic targets.

Methods

Overview of methods

Figure 1 presents the flowcharts for single-disease X-WAS and pleiotropy analyses. We

conducted TWASs and PWASs for each single disease to generate summary statistics.

Next, we examined pleiotropy for PAD-T2D and PAD-CAD comorbidities, assessing

SNPs, predicted transcripts, and predicted proteins via PLACO. The factors identified

were further evaluated for single-disease association and vertical pleiotropy. Validated

pleiotropic components were quantified for their contributions to genome-wide genetic

correlations and categorized into newly defined pleiotropy models.

GWAS summary statistics

We conducted a meta-analysis of large-scale GWAS summary statistics from the Million

Veteran Program (MVP)[8] and UK Biobank (UKB) European studies on PAD using

METAL[19]. The MVP is a large cohort study involving participants from 63 VA Medical

Centers across the United States. Specifically, this GWAS includes 24,009 PAD cases

and 150,983 non-PAD controls of Non-Hispanic White ancestry. Details of genotype

quality control procedures are provided in the previous study[8]. After genotype

imputation, SNPs were filtered according to strict quality criteria. A total of 17,577,362

SNPs were analyzed for associations with PAD using a logistic regression model

adjusted for age, sex, and the top five genetic principal components (PCs). We

accessed the summary statistics through dbGaP (dbGaP Study Accession:

phs001672.v11, Approved Project Number: 32518).

The UKB study comprises genotype and phenotype data from 502,618 participants

recruited from 22 assessment centers in the UK between 2006 and 2010[20]. Our analysis

was restricted to subjects of White European ancestry, as defined by self-reported

records and genetic ancestry described previously[21]. PAD cases and controls were

identified using self-reports and medical records (the 9th and 10th versions of the

International Classification of Diseases [ICD-9 and ICD-10], and OPCS-4)

(Supplemental Table 1). We included 13,418,147 imputed SNPs with imputation scores

≥ 0.8 and Minor allele frequency (MAF) ≥ 0.001. We performed GWAS for PAD on the

full set of directly genotyped and imputed variants (N=13,418,147) using REGENIE[22].

To adjust for confounding and potential bias due to population stratification, sex, age at

recruitment, and the top 10 PCs calculated from the directly genotyped variants were

included as covariates. The details can be found in the previously paper[23].

For T2D and CAD, we used established large-scale GWAS summary statistics for

European subjects[24,25]. Sample sizes for these analyses are provided in Table 1.

Single-omic X-WAS

We used the S-PrediXcan framework[26] for TWAS and PWAS, integrating GWAS summary statistics and established prediction models from GTEx V8 whole blood tissue[27] and Atherosclerosis Risk in Communities Study (ARIC) plasma proteins[28], respectively. Details of the TWAS and PWAS can be found in the previous study[29]. Lambda 1,000 (λ_{1000}) was calculated for both TWAS and PWAS. λ_{1000} is a measurement of genomic inflation scaled to 1000 cases and 1000 controls using the equation: $\lambda_{1000} = 1 + (\lambda_{obs} - 1) \times (\frac{1}{n_{case}} + \frac{1}{n_{control}})/(\frac{1}{1000_{case}} + \frac{1}{1000_{control}})$ where λ_{obs} is the observed genomic inflation factor, and n_{case} and $n_{control}$ are the number of cases and controls included in the GWAS summary statistics. A λ_{1000} less than or equal to 1.05 indicates an unbiased X-WAS[30].

Genome-wide genetic correlation

We calculated the genome-wide genetic correlations between PAD and CAD, as well as PAD and T2D, using LD Score regression (LDSC)[31]. The same GWAS summary statistics described earlier were used for this analysis, restricting to SNPs with MAFs greater than 0.05 in the summary statistics and those present in 1000 Genomes European genotype data. In total, 951,966 SNPs were included for the PAD-CAD correlation and 999,704 SNPs for the PAD-T2D correlation.

Single-omic pleiotropy analysis

PLACO[32] is a method that tests for pleiotropy by evaluating the null hypothesis that a variant is associated with at most one of two traits against the alternative hypothesis

that it is associated with both traits. This method was used to identify pleiotropic SNPs

with GWAS summary statistics for the diseases of interest. In brief, for each variant

shared between two GWAS datasets, PLACO de-correlates the two Z scores and

calculates an approximate asymptotic p-value for the hypothesis testing. Originally

designed for SNP-level pleiotropy analysis, we extended PLACO to transcriptome and

proteome levels using summary statistics from TWAS and PWAS. To account for

multiple comparisons, we applied the FDR control method[33] in an omic- and disease

pair-specific manner.

PLACO uses the product of two Z scores for hypothesis testing, but one limitation of this

method is that a strong association for one trait can disproportionately influence the

result. In other words, if one SNP, predicted transcript, or predicted protein is strongly

associated with one disease but not the other, PLACO may still generate a small p-

value. To address this, we filtered out SNPs with p-values greater than 5×10^{-6} for either

disease and excluded predicted transcripts or proteins with p-values greater than 0.05

for either disease. Additionally, we performed LD clumping via PLINK 1.9[34] to obtain

independent pleiotropic SNPs. We set the r^2 threshold at 0.2 and used a default window

size of 250 kilobases (kb). No p-value thresholds were set for index SNPs.

To investigate whether the pleiotropy signals identified were vertical or horizontal, we

conducted adjusted association analyses using two models with individual-level

genotype and phenotype data from UKB: (1) CAD/T2D ~ PAD + SNP/predicted

transcript/predicted protein + covariates, and (2) PAD ~ CAD/T2D + SNP/predicted

transcript/predicted protein + covariates. The covariates included age at recruitment, sex, and the top 10 genetic PCs. Due to our interest in dissecting signals between correlated and uncorrelated pleiotropy, we only focused on those signals that demonstrated some evidence of horizontal pleiotropy by only keeping those variants with at least nominally significant signals (p-values < 0.05) in both models.

Contributions to genetic covariance

After validating the pleiotropic signals, we assessed their contributions to genome-wide genetic covariances using a leave-one-out approach. Specifically, we first identified SNPs in LD ($r^2>0.2$) with the corresponding pleiotropic SNPs, eQTLs for pleiotropic predicted transcripts, or pQTLs for pleiotropic proteins. We then removed these SNPs from the GWAS summary statistics and calculated the genetic covariances using the truncated summary statistics through LDSC. We compared these leave-one-out genetic covariances with the genome-wide genetic covariances.

Furthermore, to determine whether the reduction in the number of SNPs could fully explain changes in genetic covariances, we conducted a permutation test with randomly selected regions. Specifically, we divided the summary statistics into near-independent LD regions through LD clumping and randomly selected the same number of regions as the pleiotropic components. SNPs within these regions were removed, and genetic covariances were recalculated from the summary statistics. The p-value for the permutation test was computed as the proportion of permutations in which the difference between the permuted genetic covariance and the overall genetic covariance

exceeded the difference observed between pleiotropic genetic covariances and the overall genetic covariance. We conducted 1,000 permutations.

Classification of pleiotropic signals

To better understand the molecular processes underlying pleiotropy, we classified pleiotropic components into different pleiotropy models. Each model consists of four layers: SNP, transcript, protein, and phenotype. In each layer, except for the phenotype layer, we assume either one or two signals. In total, we established eight pleiotropy models to reflect these different signal patterns (Figure 2).

Model 1 represents completely correlated pleiotropy, while Model 8 represents completely uncorrelated pleiotropy. Models 2 to 7 represent partially correlated pleiotropy, where one of two of the omic layers contains a single signal, while the remaining levels have two signals. We analyzed pleiotropic findings by omic level as follows.

We categorized pleiotropic SNPs into pleiotropic eQTLs and non-eQTLs based on GTEx v8 eQTLs in whole blood tissue. Pleiotropic eQTLs were classified into Models 1, 2, 3, and 5 if the corresponding gene(s) were pleiotropic in both TWAS and PWAS. They were assigned to Models 4 and 6 if the gene(s) were pleiotropic in TWAS but not in PWAS, and to Model 7 if not pleiotropic in either. Non-eQTLs were placed into Model 8, and we investigated potential eQTLs or pQTLs nearby (±500 kb) for additional details.

At the transcriptome level, we checked the PLACO results for the corresponding

predicted proteins. Predicted transcripts were classified into Models 1, 2, 3, and 5 if the

predicted protein(s) were pleiotropy. Otherwise, they were assigned to Models 4 and 6.

For proteins, they were fitted to models 1, 2, 3, and 5. It is important to note that we

assumed that the eQTLs for pleiotropic transcripts, pQTLs for pleiotropic proteins, and

transcripts for pleiotropic proteins exhibit the same pleiotropic effects.

Statistical analysis

Several sensitivity analyses were conducted to evaluate the robustness of our results.

First, we conducted colocalization analyses for pleiotropic genes identified in TWAS and

PWAS to assess consistency of findings across methods. Specifically, we analyzed

whether eQTLs for genes identified in TWAS or pQTLs for genes identified in PWAS

colocalized between the two diseases (PAD-CAD or PAD-T2D) using the coloc.abf

function implemented in the coloc R package[35]. A posterior probability larger than 0.8

for either PP3 or PP4 suggests the presence of pleiotropy. Second, given that PLACO

results may be affected by sample overlap between summary statistics, we applied

PLACO+[36], an enhanced version of PLACO designed to account for sample overlap, to

re-evaluate our findings. Finally, we examined tissue specificity of the TWAS results by

repeating analyses using TWAS models derived from disease-relevant tissues. For PAD,

we used models from tibial artery tissue; for CAD, from aorta and coronary artery

tissues; and for T2D, from pancreatic tissue. We then re-ran PLACO using genes

initially identified in whole blood TWASs. Genes that remained significant across tissues

were considered robust to the choice of tissue model.

To account for the increased type I error rate due to multiple comparisons, we applied

the FDR control method[33] unless otherwise specified. Most of the analyses were

conducted using R version 4.2.

Results

Pleiotropy for PAD-T2D comorbidity

The same summary statistics were used to estimate the genetic correlations between

PAD and T2D via LDSC. A strong positive correlation was found between PAD and T2D

(0.56, p-value=2.17×10^{-50}).

We generated TWAS and PWAS summary statistics that did not indicate any population

stratification ($\lambda_{1000} < 1.05$; Supplemental Figure 1). Next, we investigated specific SNPs,

predicted transcripts, and predicted proteins that were pleiotropic for PAD and T2D.

Among 8,407,719 shared SNPs between the GWAS summary statistics for T2D and

PAD, 11,924 exhibited significant pleiotropic effects as identified by PLACO (p-value ≤

7.09×10^{-5}), and 711 SNPs had univariate GWAS p-values less than 5×10^{-6} for both PAD

and T2D. After LD clumping, 15 independent pleiotropic SNPs remained. Applying

PLACO to TWAS summary statistics identified 27 pleiotropic predicted transcripts (p-

value ≤ 1.75×10^{-4}), of which 25 were nominally significant in single-disease TWAS

analyses. PLACO also revealed 6 pleiotropic predicted proteins, all significantly

associated with both PAD and T2D (p-value < 0.05). We further validated the pleiotropic

components using two regression models. We kept 5 SNPs, 2 predicted transcripts, and

2 predicted proteins that were nominally significant in both models (Table 2). We further

conducted several sensitivity analyses to assess the robustness of our results. In the

colocalization analysis, three genes (*C4A*, *DDAH2* and *APOE*) showed high posterior

probabilities (>0.8) for either hypothesis 3 or 4, suggesting evidence of pleiotropy

signals (Supplemental Table 2). In contrast, *PLEKHA1* exhibited a high posterior

probability for hypothesis 2 (0.96), suggesting that additional validation is needed to

confirm its pleiotropic role. When repeating the analysis using PLACO+, all the variants

and genes we identified remained significant (<0.05), supporting the robustness of our

findings to potential sample overlaps (Supplemental Table 3). When assessing the

tissue specificity, *C4A* remained significant (p-value=4.4×10^{-6}) when using TWAS

models derived from tibial artery tissue for PAD and pancreatic tissue for T2D. In

contrast, *DDAH2* did not have a valid prediction model available in either tissue,

precluding further evaluation.

We assessed the contributions of 9 pleiotropic components to the genome-wide genetic

covariance between PAD and T2D using a leave-one-out strategy. These components

in aggregate accounted for 2.8% of the genetic covariance, with a significant p-value

from the permutation test (p-value < 0.001) (Table 3). Notably, rs1333045 and

rs2138161 each explained 1.4%, ranking highest among all components. These results

further validated the pleiotropic effects of the identified components.

We defined 8 pleiotropy models (Figure 2 A) and classified the pleiotropic components

across omic layers (Figure 2 B-D). Among the 5 pleiotropic SNPs, rs582118 was an

eQTL for *ABO* in the whole blood tissue; however, the predicted expression of *ABO* was not associated with either PAD or T2D, placing it with Model 7. The remaining 4 SNPs were not eQTLs in the whole blood tissue and were categorized under Model 8. Notably, rs149027146 was in LD with eQTLs for *ACP2*, *C1QTNF4*, *MYBPC3*, *NUP160*, *PTPRJ*, and *SLC39A13*. The predicted expressions of the latter five genes were nominally associated with T2D, but none were associated with PAD, indicating the need to explore additional eQTLs related to PAD near this variant. For pleiotropic transcripts, the corresponding proteins for both *DDAH2* and *C4A* were not mapped in ARIC. No specific model among Models 1 to 6 can be assigned to these two genes. For pleiotropic protein expressions, *APOE* and *PLEKHA1* were classified under Models 1, 2, 3, and 5.

Pleiotropy for PAD-CAD comorbidity

The genome-wide genetic correlation between PAD and CAD was 0.69 (p-value=4.54×10^{-65}). The summary statistics of GWAS, TWAS, and PWAS for CAD also showed stable λ_{1000} (Supplemental Figure 1). We then applied PLACO to the summary statistics for PAD and CAD. After controlling the FDR at 0.05, we identified 17,746 pleiotropic SNPs, 43 pleiotropic predicted transcripts, and 9 pleiotropic predicted proteins. To refine the results, we excluded SNPs with p-values ≥ 5×10^{-6} and predicted transcripts or proteins with p-values ≥ 0.05 for both PAD and CAD. We then performed LD clumping to remove correlated SNP. In total, 60 SNPs, 40 predicted transcripts, and 9 predicted proteins were kept for further analyses. In addition, we explored the potential for vertical pleiotropy by assessing associations with one disease while adjusting for the other. Components with at least nominal significance (p < 0.05) in both

models were retained. The final list consisted of 33 SNPs, 2 predicted transcripts, and 2 predicted proteins (Table 2). Among the four identified genes, *LPL* was the only one showing clear evidence of pleiotropy in the colocalization analyses (Supplemental Table 2). *CTD-2228A4.1* and *STAT3* exhibited modest pleiotropic signals, with the highest posterior probabilities corresponding to hypothesis 4, whereas *PLEKHA1* demonstrated a higher probability for hypothesis 2. Furthermore, our findings were robust to potential sample overlaps, as all associations remained significant when re-evaluated using PLACO+ (Supplemental Table 3). Neither *CTD-2228A4.1* nor *LPL* had valid prediction models available in the disease-relevant tissues and therefore no tissue-specificity analysis was conducted.

The leave-one-out analysis revealed that, collectively, 37 components explained 9.15% of the genetic covariance between PAD and CAD (permutation p-value<0.001) (Table 3). The top contributing component was rs4977574, accounting for 3.27% (permutation p-value = 0). Notably, rs16905599 had a negative contribution to the genetic covariance (-0.65%, permutation p-value < 0.001). These results further supported the pleiotropy of identified components for PAD-CAD.

Among the 33 pleiotropic SNPs, 9 were identified as eQTLs in whole blood tissue, with 4 of these associated with the expression of *SLC22A1*. These corresponding genes were not significant in the PLACO analysis, suggesting Model 7, except for one SNP, rs111516643, which was an eQTL for *SMARCA4*–a gene not analyzed in TWAS. The current results were not sufficient to distinguish between Models 1 to 7 for rs111516643.

The remaining 24 SNPs were not eQTLs in whole blood tissue and were assigned to Model 8. Specifically, rs17696736 was in LD with eQTLs for *ALDH2*, *MAPKAPK5-AAS1*, and *TMEM116*, but none were significantly associated with PAD in the TWAS, suggesting other nearby genes linked to PAD. Regarding the two pleiotropic predicted transcripts, *CTD-2228a4.1* was not a protein-coding gene and might regulate the protein expression of other genes through Models 1 to 6. The protein for *LPL* was not mapped in ARIC, and we cannot distinguish Models 1 to 6. The pleiotropic predicted protein expressions of *PLEKHA1* and *STAT3* were assigned to Models 1, 2, 3, and 5.

Discussion

This study employed a multi-omic framework to investigate the shared genetic architecture between PAD and two related diseases–T2D and CAD. For PAD-T2D, we identified 5 SNPs, 2 predicted transcripts, and 2 predicted proteins that collectively contributed 2.8% to the genome-wide genetic covariance. Similarly, the PAD-CAD analysis revealed 33 SNPs, 2 predicted transcripts, and 2 predicted proteins, accounting for 9.15% of the genetic covariance. Furthermore, we proposed eight pleiotropy models and categorized our findings accordingly. These results enhance our understanding of the genetic risk profiles of PAD with its comorbidities, T2D and CAD.

Analyzing PAD alongside related diseases enhances the power to identify risk factors and facilitates the discovery of variants and genes not previously linked to PAD. For example, our analysis revealed that rs2138161 was associated with both PAD and T2D despite limited prior evidence of its involvement in PAD. Notably, previous studies have

demonstrated that the C allele of rs2138161 is linked to an increased risk of metabolic

syndrome among European subjects in UKB[37], an increased risk of cardiometabolic

multimorbidity (CMM), defined as the coexistence of more than two diseases of T2D,

CAD, and stroke, in UKB subjects[38], and elevated levels of multiple lipid metabolites[39].

These findings suggest that rs2138161 may play a role in shared biological pathways

underlying metabolic and vascular dysfunction. This observation underscores the value

of pleiotropic analyses in uncovering genetic risk factors for complex diseases and

highlights the need for further functional studies to elucidate the mechanistic role of

rs2138161 in PAD pathogenesis.

Further, the predicted protein expression level of *PLEKHA1* was positively associated

with both PAD and CAD but inversely associated with T2D. This gene has been

previously implicated in T2D[40], osteoporosis[40], and neurodegenerative disorders such

as Alzheimer's disease (AD) and age-related macular degeneration[41]. *PLEKHA1* is

closely related to the PI3K/AKT signaling pathway–a key mediator in the development

of ischemic diseases affecting the heart, brain, and limbs and a recognized therapeutic

target[42,43]. Our results suggest that the PLEKHA1 protein may serve as a potential

therapeutic target for PAD via modulation of the PI3K/AKT pathway. This differential

association across related conditions underscores the complex role of *PLEKHA1* in both

vascular and metabolic pathogenesis. It highlights the need for further mechanistic

studies to clarify its contributions to these disease processes.

Our study identified genetic components underlying the comorbidity of PAD with T2D and CAD. In the analysis for PAD and T2D, we have identified two predicted transcripts (*C4A* and *DDAH2*) and two predicted proteins (*APOE* and *PLEKHA1*) as pleiotropy factors, with all four genes previously linked to AD[41,44–47]. Our findings are consistent with earlier research demonstrating overlapping genetic risk among cardiovascular diseases, AD, and T2D[41,48], which supports the idea of common pathogenic mechanisms. Chronic inflammation–a known contributor to AD, atherosclerosis, and T2D[49,50]–may serve as a central mediator of this genetic overlap. Future studies of the effects of similar inflammatory pathways on the comorbidity of PAD and T2D need to be conducted to clarify the complex mechanisms further.

Lipids and lipoproteins play important roles in the pathogenesis of atherosclerosis[51,52]. Our analyses identified several lipid-related genetic factors that exhibit pleiotropy effects on PAD and CAD. For example, we found rs140570886, a well-established risk variant for elevated lipoprotein (a) levels located in the *LPA* gene region[53], that was associated with an increased risk of both PAD and CAD. In addition, the predicted transcript level of *LPL* was inversely associated with these two diseases. This gene encodes lipoprotein lipase, a key enzyme in lipid metabolism that also influences atherosclerotic development[54,55]. Our results suggest that pathways involved in lipid metabolism may underlie the shared genetic basis of PAD and CAD, underscoring the clinical importance of effective lipid management in atherosclerotic patients.

The molecular basis of pleiotropy has been extensively discussed. Traditional models categorize a mutation's impact on multiple phenotypes into three tiers–gene, gene product, and function[56]. In our study, we extended this framework by adopting a multi-omic perspective that integrates SNPs, transcripts, and proteins (Figure 2). Our multi-layered models clarify how genetic variation concurrently influences two complex diseases through changes in gene and protein expression. By elucidating these molecular mechanisms, our framework highlights potential biological pathways and therapeutic targets for future research.

A major strength of our study is the application of joint tests using PLACO to assess whether genetic variants, predicted transcripts, or predicted proteins are simultaneously associated with two diseases. Prior investigations into PAD-related pleiotropy have predominantly relied on candidate SNP association[10], MR[9], multi-trait association[11], or PGS analyses[9,12]. In contrast, few studies have employed joint tests specifically designed to detect pleiotropy at multiple molecular levels. Our findings provide direct statistical evidence of pleiotropy, and we extend the PLACO framework to encompass transcriptomic and proteomic analyses. This multi-omic approach not only reinforces the evidence of shared genetic underpinnings but also offers new insights into the molecular mechanisms driving the comorbidities of PAD with T2D and CAD.

Several limitations should be acknowledged. First, the TWAS and PWAS summary statistics are derived from models that predict gene and protein expression levels based on genetic variants rather than from direct measurements. As such, the accuracy of

these predictions is critical. Additionally, these predicted expression levels should not be interpreted as direct measurements due to variations in the heritability of gene and protein expression and the exclusion of non-genetic risk factors from the models. Instead, the observed associations reflect the relationship between the genetic component of omic levels and disease risk.

Second, our pleiotropy models integrate each component into a single framework, implicitly assuming that these components act independently. Additionally, we focused exclusively on cis effects for both transcripts and proteins in our prediction and subsequent analyses, despite the potential significance of trans effects in mediating pleiotropy. Future studies should incorporate gene interactions and trans effects to capture a more comprehensive picture of pleiotropic mechanisms.

Third, we did not perform simulation analyses to evaluate the false positive rate or statistical power of extending PLACO to TWAS and PWAS, as such evaluations were beyond the scope of this study. To assess the robustness of the pleiotropic gene and protein associations identified by our method, we conducted colocalization analyses. Most results showed at least suggestive evidence of pleiotropy, whereas the predicted protein expression of *PLEKHA1* did not demonstrate evidence of pleiotropy in either the PAD-T2D or PAD-CAD pairs. Further studies should be conducted to more comprehensively evaluate the performance of PLACO in multi-omic contexts.

Fourth, gene and protein expression levels vary across tissue types, and therefore our findings based on whole-blood TWAS and PWAS may not fully generalize to other disease-relevant tissues. To evaluate potential tissue specificity, we conducted a sensitivity analysis using TWAS models derived from tissues pathologically relevant to each disease. Among the four genes identified, only *C4A* had a valid prediction model in each of the selected tissues, and its pleiotropic association was successfully replicated. The remaining three genes, although expressed in these tissues, lacked valid prediction models and thus could not be evaluated. Future studies incorporating more comprehensive and tissue-specific transcriptomic resources will be important for further investigating the tissue specificity of these pleiotropy signals.

Lastly, our study was limited to genetically confirmed European subjects due to the small sample sizes of GWAS in other populations and the absence of gene and protein expression prediction models for non-European groups. Given the differences in disease prevalence, heritability, and genetic architecture across ancestries, our findings may not be generalizable to non-European populations. Future studies will aim to incorporate larger, more diverse datasets to validate and extend these results.

Conclusions

To sum up, our multi-omic analysis investigated pleiotropic genetic factors associated with two disease pairs–PAD with T2D and PAD with CAD. By integrating the results of joint tests across SNP, predicted transcript, and predicted protein levels, we developed eight pleiotropy models to elucidate the molecular process involved in pleiotropy. These

findings provide valuable insights into the genetic etiology of both individual diseases and their comorbidities.

Data Availability

The GWAS summary statistic used in this study is available through the CARDIoGRAMplusC4D website (http://www.cardiogramplusc4d.org/) for CAD and the DIAGRAM website (https://diagram-consortium.org/downloads.html) for T2D. The GWAS summary statistic for PAD developed using the MVP cohort is available via application through dbGaP (dbGaP Study Accession: phs001672.v11). The meta-analyzed GWAS for PAD used in this study is available from the corresponding author upon reasonable request. The elastic net models used in TWAS can be download via https://zenodo.org/records/3519321#.XfEKwtF7m90. The PWAS prediction models can be downloaded via http://nilanjanchatterjeelab.org/pwas/ . The TWAS and PWAS summary statistics generated in this study are available from the corresponding author upon reasonable request.

Acknowledgements

The authors would like to thank the researchers and participants of the United Kingdom Biobank. All data was accessed as part of project 32285 from the United Kingdom Biobank. We thank the Yale Center for Research Computing for the use of the McCleary High Performance Computing cluster.

Funding Statement

This work was supported by a grant from the National Institutes of Health-National Heart, Lung, and Blood Institute (R01HL145660 to ATD), a grant from National Institutes of Health-National Institute of General Medical Sciences (R01GM134005 to HZ), and a

grant from National Institutes of Health-National Human Genome Research Institute (R01HG012735 to HZ).

Author Contributions

Conceptualization: JH, HZ, AD; Data curation: JH, AD; Formal analysis: JH; Funding acquisition: HZ, AD; Investigation: JH, HZ, AD; Methodology: JH, HZ, AD; Project administration: AD; Resources: HZ, AD; Software: JH; Supervision: HZ, AD; Validation: JH; Visualization: JH, AD; Wring-original draft: JH, AD; Wriging-review & editing: all authors.

Ethics Declaration

This research was conducted using the UK Biobank Resource (application number 32285). The UK Biobank study was conducted under generic approval from the National Health Services' National Research Ethics Service. The present analyses were conducted in accordance with the Declaration of Helsinki and approved by the Human Investigations Committee at Yale University (2000026836 for UK Biobank). The patients/participants provided their written informed consent to participate in this study.

Conflicts of interest

CIOC is consultant for SVS-PSO, EnVVeno Medical, has IP of patent U.S.S.N. 10,524,89, and has received research support from Yale department of Surgery, SVS, AVF, CT Innovation, VSGNE, NIH, Boston Scientific, Medtronic, EnVVeno Medical, Inari Medical.

Declaration of AI and AI-assisted technologies in the writing process

During the preparation of this work the author(s) used ChatGPT-5 in order to improve readability and language. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

References

1. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UKA, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *The Lancet*. 2013;382(9901):1329–1340.
2. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *The Lancet. Global health*. 2019;7(8):e1020–e1030.
3. Chase-Vilchez AZ, Chan IHY, Peters SAE, Woodward M. Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: a systematic review and meta-analysis. *Cardiovascular diabetology*. 2020;19(1):151.
4. Barnes JA, Eid MA, Creager MA, Goodney PP. Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease. *Arteriosclerosis, thrombosis, and vascular biology*. 2020;40(8):1808–1817.
5. Fowkes FGR, Aboyans V, Fowkes FJI, McDermott MM, Sampson UKA, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. *Nature reviews. Cardiology*. 2017;14(3):156–170.
6. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, Huffman JE, Assimes TL, Lorenz K, Zhu X, Hilliard AT, Judy RL, Huang J, Lee KM, Klarin D, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nature genetics*. 2020;52(7):680–691.
7. Bosque-Plata L del, del Bosque-Plata L, Martínez-Martínez E, Espinoza-Camacho MÁ, Gragnoli C. The Role of *TCF7L2* in Type 2 Diabetes. *Diabetes*. 2021;70(6):1220–1228.
8. Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q, Huffman JE, Natarajan P, Arya S, Small A, Sun YV, Vujkovic M, Freiberg MS, et al. Genome-wide association study of peripheral artery disease in the Million Veteran Program. *Nature medicine*. 2019;25(8):1274–1279.
9. Xiu X, Zhang H, Xue A, Cooper DN, Yan L, Yang Y, Yang Y, Zhao H. Genetic evidence for a causal relationship between type 2 diabetes and peripheral artery disease in both Europeans and East Asians. *BMC medicine*. 2022;20(1):300.
10. Safarova MS, Fan X, Austin EE, van Zuydam N, Hopewell J, Schaid DJ, Kullo IJ. Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease-Brief Report. *Arteriosclerosis, thrombosis, and vascular biology*. 2019;39(6):1227–1233.
11. Bellomo TR, Bone WP, Chen BY, Gawronski KAB, Zhang D, Park J, Levin M, Tsao N, Klarin D, Lynch J, Assimes TL, Gaziano JM, Wilson PW, Cho K, Vujkovic M, et al. Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci. *Frontiers in genetics*. 2021;12:787545.
12. Ntalla I, Kanoni S, Zeng L, Giannakopoulou O, Danesh J, Watkins H, Samani NJ, Deloukas P, Schunkert H, UK Biobank CardioMetabolic Consortium CHD Working Group. Genetic Risk Score for Coronary Disease Identifies Predispositions to

Cardiovascular and Noncardiovascular Diseases. *Journal of the American College of Cardiology*. 2019;73(23):2932–2942.

13. Newman JD, Cornwell MG, Zhou H, Rockman C, Heguy A, Suarez Y, Cheng HS, Feinberg MW, Hochman JS, Ruggles KV, Berger JS. Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease. *Arteriosclerosis, thrombosis, and vascular biology*. 2021;41(4):1521–1533.

14. Viñuela A, Varshney A, van de Bunt M, Prasad RB, Asplund O, Bennett A, Boehnke M, Brown AA, Erdos MR, Fadista J, Hansson O, Hatem G, Howald C, Iyengar AK, Johnson P, et al. Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D. *Nature communications*. 2020;11(1):4912.

15. Yuan S, Titova OE, Zhang K, Chen J, Li X, Klarin D, Åkesson A, Damrauer SM, VA Million Veteran Program, Larsson SC. Circulating proteins and peripheral artery disease risk: observational and Mendelian randomization analyses. *European heart journal open*. 2023;3(3):oead056.

16. Elhadad MA, Jonasson C, Huth C, Wilson R, Gieger C, Matias P, Grallert H, Graumann J, Gailus-Durner V, Rathmann W, von Toerne C, Hauck SM, Koenig W, Sinner MF, Oprea TI, et al. Deciphering the Plasma Proteome of Type 2 Diabetes. *Diabetes*. 2020;69(12):2766–2778.

17. Li L, Chen Z, von Scheidt M, Li S, Steiner A, Güldener U, Koplev S, Ma A, Hao K, Pan C, Lusis AJ, Pang S, Kessler T, Ermel R, Sukhavasi K, et al. Transcriptome-wide association study of coronary artery disease identifies novel susceptibility genes. *Basic research in cardiology*. 2022;117(1):6.

18. Yang F, Xu F, Zhang H, Gill D, Larsson SC, Li X, Cui H, Yuan S. Proteomic insights into the associations between obesity, lifestyle factors, and coronary artery disease. *BMC medicine*. 2023;21(1):485.

19. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* . 2010;26(17):2190–2191.

20. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*. 2015;12(3):e1001779.

21. DeWan AT, Cahill ME, Cornejo-Sanchez DM, Li Y, Dong Z, Fabiha T, Sun H, Wang G, Leal SM. Variants in JAZF1 are associated with asthma, type 2 diabetes, and height in the United Kingdom biobank population. *Frontiers in genetics*. 2023;14:1129389.

22. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C, O'Dushlaine C, Barber M, Boutkov B, Habegger L, Ferreira M, Baras A, Reid J, Abecasis G, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nature genetics*. 2021;53(7):1097–1103.

23. Jiaqi Hu, Dana Alameddine, He Wang, Cassius I. Ochoa Chaar, Andrew T. DeWan. PAD-associated genetic variants are more strongly associated with surgical intervention than premature onset. *Unpublished manuscript*.

24. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, Yu GZ, Rüeger S, Speidel L, Kim YJ, Horikoshi M, Mercader JM, Taliun D, Moon S, Kwak S-H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of

diverse populations for discovery and translation. *Nature genetics*. 2022;54(5):560–572.

25. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nature genetics*. 2022;54(12):1803–1815.

26. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, Torstenson ES, Shah KP, Garcia T, Edwards TL, Stahl EA, Huckins LM, GTEx Consortium, Nicolae DL, Cox NJ, et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nature communications*. 2018;9(1):1825.

27. Barbeira AN, Bonazzola R, Gamazon ER, Liang Y, Park Y, Kim-Hellmuth S, Wang G, Jiang Z, Zhou D, Hormozdiari F, Liu B, Rao A, Hamel AR, Pividori MD, Aguet F, et al. Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. *bioRxiv*. 2020:814350.

28. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, Harvey B, CKDGen Consortium, Yu B, Boerwinkle E, Coresh J, Chatterjee N. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. *Nature genetics*. 2022;54(5):593–602.

29. Hu J, Lin C, Zhao H, DeWan AT. A framework for studying multi-omic risk factors and their interplay: application to coronary artery disease. *medRxiv*. 2025.

30. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu X-O, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature genetics*. 2018;50(7):968–978.

31. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh P-R, ReproGen Consortium, Psychiatric Genomics Consortium, Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan L, Perry JRB, Patterson N, Robinson EB, Daly MJ, Price AL, et al. An atlas of genetic correlations across human diseases and traits. *Nature genetics*. 2015;47(11):1236–1241.

32. Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate Cancer. *PLoS genetics*. 2020;16(12):e1009218.

33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society*. 1995;57(1):289–300.

34. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. *American journal of human genetics*. 2007;81(3):559–575.

35. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics*. 2014;10(5):e1004383.

36. Park J, Ray D. A robust pleiotropy method with applications to lipid traits and to

inflammatory bowel disease subtypes with sample overlap. *HGG advances*. 2025;7(1):100501.

37. Lind L. Genome-wide association study of the metabolic syndrome in UK biobank. *Metabolic syndrome and related disorders*. 2019;17(10):505–511.

38. Zhao C, Ma T, Cheng X, Zhang G, Bai Y. Genome-wide association study of cardiometabolic multimorbidity in the UK Biobank. *Clinical genetics*. 2024;106(1):72–81.

39. Karjalainen MK, Karthikeyan S, Oliver-Williams C, Sliz E, Allara E, Fung WT, Surendran P, Zhang W, Jousilahti P, Kristiansson K, Salomaa V, Goodwin M, Hughes DA, Boehnke M, Fernandes Silva L, et al. Genome-wide characterization of circulating metabolic biomarkers. *Nature*. 2024;628(8006):130–138.

40. Hu Y, Tan L-J, Chen X-D, Greenbaum J, Deng H-W. Identification of novel variants associated with osteoporosis, type 2 diabetes and potentially pleiotropic loci using pleiotropic cFDR method. *Bone*. 2018;117:6–14.

41. Caputo V, Termine A, Strafella C, Giardina E, Cascella R. Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes. *World journal of diabetes*. 2020;11(5):155–164.

42. Ghafouri-Fard S, Khanbabapour Sasi A, Hussen BM, Shoorei H, Siddiq A, Taheri M, Ayatollahi SA. Interplay between PI3K/AKT pathway and heart disorders. *Molecular biology reports*. 2022;49(10):9767–9781.

43. Samakova A, Gazova A, Sabova N, Valaskova S, Jurikova M, Kyselovic J. The PI3k/Akt pathway is associated with angiogenesis, oxidative stress and survival of mesenchymal stem cells in pathophysiologic condition in ischemia. *Physiological research*. 2019;68(Suppl 2):S131–S138.

44. Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. *Journal of neuroinflammation*. 2020;17(1):354.

45. Bennett S, Grant M, Creese AJ, Mangialasche F, Cecchetti R, Cooper HJ, Mecocci P, Aldred S. Plasma levels of complement 4a protein are increased in Alzheimer's disease. *Alzheimer disease and associated disorders*. 2012;26(4):329–334.

46. Li QS, Sun Y, Wang T. Epigenome-wide association study of Alzheimer's disease replicates 22 differentially methylated positions and 30 differentially methylated regions. *Clinical epigenetics*. 2020;12(1):149.

47. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. *Lancet neurology*. 2021;20(1):68–80.

48. Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A, Wen N, Hess CP, Dillon WP, Glastonbury CM, Glymour M, Yokoyama JS, Elahi FM, Rabinovici GD, Miller BL, et al. Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. *Acta neuropathologica*. 2019;137(2):209–226.

49. Jayaraman A, Pike CJ. Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions. *Current diabetes reports*. 2014;14(4):476.

50. Lathe R, Sapronova A, Kotelevtsev Y. Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature. *BMC geriatrics*. 2014;14(1):36.

51. Carmena R, Duriez P, Fruchart J-C. Atherogenic lipoprotein particles in

atherosclerosis. *Circulation*. 2004;109(23 Suppl 1):III2-7.

52. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. *Annals of internal medicine*. 1991;115(3):209–218.

53. Mack S, Coassin S, Rueedi R, Yousri NA, Seppälä I, Gieger C, Schönherr S, Forer L, Erhart G, Marques-Vidal P, Ried JS, Waeber G, Bergmann S, Dähnhardt D, Stöckl A, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. *Journal of lipid research*. 2017;58(9):1834–1844.

54. Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, Goliopoulou A, Kalogeras K, Tsigkou V, Kalpis A, Paschou SA, Theofilis P, Vavuranakis M, Tousoulis D, Siasos G. Lipoprotein(a) in atherosclerotic diseases: From pathophysiology to diagnosis and treatment. *Molecules (Basel, Switzerland)*. 2023;28(3):969.

55. Li Y, He P-P, Zhang D-W, Zheng X-L, Cayabyab FS, Yin W-D, Tang C-K. Lipoprotein lipase: from gene to atherosclerosis. *Atherosclerosis*. 2014;237(2):597–608.

56. Hu JX, Thomas CE, Brunak S. Network biology concepts in complex disease comorbidities. *Nature reviews. Genetics*. 2016;17(10):615–629.

Figure Legends

Graphical Abstract

PAD: peripheral artery disease; T2D: type 2 diabetes; CAD: coronary artery disease; SNP: single nucleotide polymorphism; mRNA: messenger ribonucleic acid.

Figure 1 Flowchart of analysis.

Flowchart of methodology. We first conducted TWAS and PWAS across three diseases, and ran PLACO on SNP, predicted transcripts, and predicted proteins for pleiotropy factors. Finally, we integrated pleiotropy results across multi-omic levels and developed pleiotropy models. GWAS: genome-wide association analysis; PAD: peripheral artery disease; T2D: type 2 diabetes; CAD: coronary artery disease; SNP: single-nucleotide polymorphism; TWAS: transcriptome-wide association analysis; PWAS: protein-wide association analysis.

Figure 2 Pleiotropy models.

Eight pleiotropy models integrating SNPs, transcripts, and proteins. (A). Definitions for eight pleiotropy models. Model 1 represents completely correlated pleiotropy, while Model 8 represents completely uncorrelated pleiotropy. Models 2 to 7 represent partially correlated pleiotropy, where one of two of the omic layers contains a single signal, while the remaining levels have two signals. (B-D). The assignment of specific factor to pleiotropy models.

Tables

Table 1 GWAS summary statistics.

Disease	GWAS	Sample sizes	Number of cases	Number of controls	Number of SNPs	Heritability (SE)	Genetic correlation with PAD (P-value)
PAD	Meta-analysis of MVP and UKB	583,679	30,824	552,855	9,789,567	0.0153 (0.0041)	
T2D	Mahajan et al. (2022)	933,970	80,154	853,816	9,980,958	0.0419 (0.0032)	0.5613 (2.17E-50)
CAD	Aragam et al. (2022)	1,347,212	181,522	1,165,690	13,851,199	0.0321 (0.0027)	0.6918 (4.54E-65)

GWAS: genome-wide association study; SNP: single-nucleotide polymorphism; SE: standard error; PAD: peripheral artery disease; T2D: type 2 diabetes; CAD: coronary artery disease. The p-value for the genetic correlation is derived from a Wald test implemented within the LDSC framework.

Table 2 Pleiotropy findings.

Chr	Pos	SNP	A1/pos_end*	z.pad	p.pad	z.D2	p.D2	p.placo	D2	study	Pleiotopy Model(s)
2	226230443	rs2138161	C	4.86	1.20E-06	13.77	3.72E-43	6.47E-21	T2D	GWAS	8
9	22119196	rs1333045	C	12.12	7.84E-34	7.92	2.34E-15	2.65E-31	T2D	GWAS	8
9	133270061	rs582118	A	-5.06	4.09E-07	-6.88	5.96E-12	2.60E-12	T2D	GWAS	7
11	48467808	rs149027146	T	4.68	2.82E-06	4.77	1.83E-06	2.25E-08	T2D	GWAS	8
17	67964738	rs59956089	C	6.74	1.61E-11	6.29	3.23E-10	9.34E-15	T2D	GWAS	8
6	31727038	DDAH2	31730617	-3.46	5.41E-04	-6.44	1.21E-10	3.03E-06	T2D	TWAS	1-6
6	31982057	C4A	32002681	-4.65	3.26E-06	-5.79	7.08E-09	1.43E-07	T2D	TWAS	1-6
10	122374696	PLEKHA1	122432354	-3.09	2.00E-03	4.00	6.35E-05	1.96E-05	T2D	PWAS	1, 2, 3, 5
19	44905791	APOE	44909393	2.61	9.13E-03	-4.71	2.51E-06	1.71E-05	T2D	PWAS	1, 2, 3, 5
1	150567391	rs932054	G	4.65	3.34E-06	6.71	1.89E-11	3.71E-11	CAD	GWAS	7
2	226230443	rs2138161	C	4.86	1.20E-06	7.11	1.17E-12	3.39E-12	CAD	GWAS	8
4	147480038	rs6841581	A	6.26	3.86E-10	11.44	2.65E-30	2.18E-23	CAD	GWAS	8
6	34809756	rs9296133	A	5.00	5.67E-07	6.32	2.64E-10	2.34E-11	CAD	GWAS	7
6	160003858	rs144078421	A	6.10	1.04E-09	13.23	5.80E-40	1.31E-25	CAD	GWAS	7
6	160130061	rs4646272	G	5.47	4.42E-08	10.61	2.55E-26	4.11E-19	CAD	GWAS	7
6	160298560	rs79390162	T	7.61	2.78E-14	13.05	6.16E-39	4.51E-32	CAD	GWAS	8
6	160330499	rs9295128	T	8.89	6.08E-19	21.96	6.60E-107	2.42E-58	CAD	GWAS	7
6	160338808	rs386453	T	-5.22	1.83E-07	-10.63	2.19E-26	3.46E-18	CAD	GWAS	8
6	160446240	rs143665477	C	5.23	1.67E-07	9.37	7.55E-21	1.73E-16	CAD	GWAS	8
6	160470865	rs182443492	A	4.80	1.55E-06	10.18	2.48E-24	4.05E-16	CAD	GWAS	8
6	160589086	rs10455872	G	14.51	9.74E-48	29.12	2.18E-186	1.17E-128	CAD	GWAS	8
6	160591981	rs140570886	C	10.79	3.67E-27	22.45	1.36E-111	3.88E-74	CAD	GWAS	7
6	160646860	rs6905073	T	-4.74	2.17E-06	-11.14	8.40E-29	5.32E-17	CAD	GWAS	8
6	160741258	rs1835346	G	4.78	1.79E-06	6.79	1.14E-11	1.50E-11	CAD	GWAS	8
6	160962047	rs143843429	G	6.70	2.09E-11	15.20	3.79E-52	1.17E-31	CAD	GWAS	8
7	19009765	rs2107595	A	6.59	4.27E-11	10.14	3.61E-24	2.71E-22	CAD	GWAS	8
7	150993088	rs3918226	T	5.15	2.56E-07	11.79	4.60E-32	1.88E-19	CAD	GWAS	8
9	21961867	rs7041637	A	6.75	1.46E-11	18.01	1.52E-72	2.24E-36	CAD	GWAS	8
9	22069145	rs16905599	A	-4.65	3.28E-06	-7.70	1.32E-14	1.68E-12	CAD	GWAS	8
9	22098575	rs4977574	G	12.96	2.00E-38	35.60	1.41E-277	1.91E-132	CAD	GWAS	8

Chr	Pos		*								
10	98130980	rs11189490	A	-5.70	1.18E-08	-5.84	5.36E-09	6.05E-12	CAD	GWAS	7
11	102924877	rs1892971	A	-5.21	1.87E-07	-6.21	5.14E-10	1.25E-11	CAD	GWAS	8
12	111466567	rs4766578	A	-6.94	3.85E-12	-11.06	2.03E-28	2.66E-25	CAD	GWAS	8
12	112049014	rs17696736	G	6.56	5.37E-11	9.30	1.36E-20	1.39E-20	CAD	GWAS	8
15	78643826	rs55988292	G	5.40	6.48E-08	-4.96	6.95E-07	5.86E-13	CAD	GWAS	7
16	56959249	rs12149545	A	-4.71	2.47E-06	-6.70	2.11E-11	2.83E-11	CAD	GWAS	8
18	22422981	rs1893250	C	5.22	1.75E-07	5.83	5.54E-09	5.01E-11	CAD	GWAS	8
18	22476030	rs2110135	C	-5.43	5.58E-08	-5.88	4.14E-09	1.66E-11	CAD	GWAS	8
19	10959957	rs111516643	T	-4.57	4.92E-06	-5.50	3.89E-08	2.79E-09	CAD	GWAS	8
19	11073161	rs73015007	A	-5.84	5.14E-09	-7.95	1.82E-15	4.89E-16	CAD	GWAS	1-7
19	11077441	rs55997232	T	-6.23	4.62E-10	-13.97	2.33E-44	2.40E-27	CAD	GWAS	8
19	11166556	rs4804573	A	-4.65	3.32E-06	-9.00	2.18E-19	3.74E-14	CAD	GWAS	8
5	17107360	CTD-2228A4.1	17107789	-2.53	1.15E-02	4.44	8.83E-06	1.67E-05	CAD	TWAS	1-6
8	19901717	LPL	19967259	-4.08	4.50E-05	-7.29	3.01E-13	1.32E-07	CAD	TWAS	1-6
10	122374696	PLEKHA1	122432354	-3.09	2.00E-03	-5.11	3.20E-07	1.65E-04	CAD	PWAS	1, 2, 3, 5
17	42313324	STAT3	42388568	-3.61	3.01E-04	-4.22	2.49E-05	1.70E-04	CAD	PWAS	1, 2, 3, 5

Chr: chromosome; Pos: position in hg38; *: effective allele for SNPs and ending position for genes. P-values for PAD, T2D, and CAD were obtained using Wald tests. The p-value for PLACO was derived from a likelihood-based composite test statistic.

Table 3 Contributions to genetic covariance.

Disease	Genetic covariance	SNP/Gene	Number of SNPs removed	Genetic covariance after removing SNPs	Number of SNPs removed in permutation	Permuted genetic covariance	P-value
		All	903	0.0139	457.34	0.0153	0
		rs4977574	20	0.0148	6.11	0.0153	0
		LPL	102	0.0152	48.06	0.0153	0.002
		STAT3	197	0.0152	133.92	0.0153	0.006
		rs143665477	46	0.0152	6.12	0.0153	0
		rs386453	53	0.0152	6.12	0.0153	0
		rs9295128	46	0.0152	6.12	0.0153	0
		CTD-2228A4.1	17	0.0153	6.13	0.0153	0
		PLEKHA1	115	0.0153	69.38	0.0153	0.004
		rs10455872	17	0.0153	6.12	0.0153	0
		rs111516643	26	0.0153	5.98	0.0153	0.001
CAD	0.0153	rs11189490	22	0.0153	6.13	0.0153	0
		rs12149545	3	0.0153	5.97	0.0153	0.001
		rs140570886	17	0.0153	6.12	0.0153	0
		rs143843429	11	0.0153	6.12	0.0153	0
		rs144078421	9	0.0153	6.12	0.0153	0
		rs17696736	2	0.0153	6.05	0.0153	0
		rs182443492	9	0.0153	6.12	0.0153	0
		rs1835346	14	0.0153	6.12	0.0153	0
		rs1892971	1	0.0153	6.11	0.0153	0
		rs1893250	1	0.0153	5.94	0.0153	0.001
		rs2107595	12	0.0153	6.14	0.0153	0
		rs2110135	13	0.0153	5.94	0.0153	0.001
		rs2138161	48	0.0153	6.11	0.0153	0

	rs3918226	9	0.0153	6.14	0.0153	0
	rs4646272	0	0.0153	6.12	0.0153	0
	rs4766578	3	0.0153	6.05	0.0153	0
	rs4804573	3	0.0153	5.98	0.0153	0.001
	rs55988292	8	0.0153	6.00	0.0153	0.001
	rs55997232	4	0.0153	5.98	0.0153	0.001
	rs6841581	4	0.0153	6.10	0.0153	0
	rs6905073	17	0.0153	6.12	0.0153	0
	rs7041637	6	0.0153	6.11	0.0153	0
	rs73015007	4	0.0153	5.98	0.0153	0.001
	rs79390162	23	0.0153	6.12	0.0153	0
	rs9296133	45	0.0153	6.14	0.0153	0
	rs932054	21	0.0153	6.06	0.0153	0
	rs16905599	7	0.0154	6.11	0.0153	0
	All	508	0.0139	324.15	0.0143	0
	rs1333045	21	0.0141	5.83	0.0143	0
	rs2138161	51	0.0141	6.21	0.0143	0
	C4A	216	0.0142	207.66	0.0143	0.001
	APOE	11	0.0143	13.25	0.0143	0.002
T2D 0.0143	DDAH2	28	0.0143	34.95	0.0143	0.002
	PLEKHA1	119	0.0143	63.33	0.0143	0.001
	rs149027146	42	0.0143	5.90	0.0143	0
	rs582118	25	0.0143	5.87	0.0143	0
	rs59956089	16	0.0143	6.16	0.0143	0

P-values were obtained using a permutation test based on 1,000 iterations.

Figure 1. Flowchart of analysis.

Figure 2. Pleiotropy models.

A. Pleiotropy models

| Phenotype | Protein | Transcript | SNP |

Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8

B. Pleiotropic SNPs

Is the SNP an eQTL in whole blood tissue?

NO → Model 8

YES ↓

Is the corresponding **gene expression** pleiotropic in our analysis?

NO → Model 7

YES ↓

Is the corresponding **protein expression** pleiotropic in our analysis?

NO → Models 4 and 6

YES ↓

Models 1, 2, 3, and 5

C. Pleiotropic predicted transcripts

eQTLs in whole blood tissue

↓

Is the corresponding **protein expression** pleiotropic in our analysis?

NO → Models 4 and 6

YES ↓

Models 1, 2, 3, and 5

D. Pleiotropic predicted proteins

eQTLs in whole blood tissue

↓

corresponding transcripts

↓

Is the **protein expression** pleiotropic in our analysis?

YES ↓

Models 1, 2, 3, and 5